ANAB AnaptysBio Inc.: Long-Term Debt to Capital Coefficient

Symbol and logo of brand AnaptysBio Inc. (ANAB)

AnaptysBio, Inc. (ANAB) develops advanced antibodies to combat immune pathologies by investing in the study of inflammatory processes. The company currently generates revenue through grants and licensing fees. This chart (separate_debt_long_eq) reflects the 23.45 metric. Future growth will depend on the completion of active clinical trials and the delivery of breakthrough scientific results for its promising drug pipeline.

ANAB - AnaptysBio Inc Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for AnaptysBio, Inc. (ANAB)

- price and consensus price forecast:
Quote Chart AnaptysBio Inc|ANAB - Analyst Consensus Forecast
- market capitalization data:
Market Value AnaptysBio, Inc.|ANAB - Enterprise Value
- book capitalization data:
Book Value per Share AnaptysBio|ANAB - Company Book Value|Market Value to Book Value anaptysbio.com|ANAB - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio AnaptysBio, Inc.|ANAB - Long-Term Debt to Capital|Short-Term Debt to Capital anaptysbio.com|ANAB - Company Total Debt|Debt to Net Assets Ratio AnaptysBio, Inc.|ANAB - Company Long-Term Debts|Short-Term Debt Volume AnaptysBio
Initial company analysis:ANAB, AnaptysBio Inc
Core merchandise of AnaptysBio, Inc.

AnaptysBio, Inc. (ANAB) transition to an outsourcing model for early-stage development reduces the business's capital intensity, which directly impacts its debt load. By analyzing the current long-term debt-to-equity ratio, an investor assesses the proportion of liabilities with maturities exceeding one year relative to the company's value, where a declining ratio indicates strengthening balance sheet stability, potentially at the expense of return on equity.

Direct competitors

Long-Term Liabilities to Equity argenx N.V.|BioNTech Group (BNTX) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Abivax S.A. (ABVX)|Long-Term Debt to Capital ADMA (ADMA Biologics)|protagonist-inc.com - Long-Term Debt to Capital|Long-Term Debt to Equity Immunovant (IMVT)|KNSA: Long-Term Debt to Capital Coefficient|GRFS (Grifols Group) - Long-Term Debt to Equity|Adaptive Biotechnologies Inc. (ADPT) - Long-Term Debt to Equity Ratio|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com (AUPH)|BioCryst Pharmaceuticals (BCRX) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Vera Therapeutics Inc (VERA)|Long-Term Debt to Capital DNTH|Pharvaris Pharma - Ratio of Long-Term Indebtedness to Capital|ABCL: Long-Term Debt to Equity|TRML: Long-Term Debt to Equity Ratio|PGEN (Precigen) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|NKTR (Nektar) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital UPB|Long-Term Debt to Equity Zenas Biopharma Inc ZBIO|Long-Term Debt to Capital Ratio immunome.com (IMNM)|GOSS: Long-Term Debt to Capital|Long-Term Liabilities to Capital KalVista Pharma KALV|Septerna Corp - Long-Term Debt to Capital|PVLA: Long-Term Debt to Capital|Long-Term Debt to Equity Savara Inc.|rigel.com (RIGL) - Long-Term Debt to Capital Ratio|ATXS (Astria Therapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital ENGN|RAPT - Long-Term Debt to Equity|Long-Term Liabilities to Equity aerovatetx.com JBIO|Long-Term Debt to Equity Ratio Aclaris Therapeutics (ACRS)|KYTX - Long-Term Loans to Capital Ratio|TLSA (Tiziana Life Sciences Ltd) - Long-Term Debt to Equity Ratio|CABA: Long-Term Liabilities to Capital|Ventyx Bio - Long-Term Debt to Equity|Theratechnologies, Inc (THTX) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital Avalo Therapeutics, Inc|Long-Term Debt to Equity eledon.com|AGEN (Agenus Inc.) - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital CLYM (Climb Bio Inc.)|ZURA: Long-Term Debt to Equity|ATYR - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio Adagene Corp (ADAG)|IMA - Long-Term Debt to Capital Coefficient|shattucklabs.com - Long-Term Debt to Capital|EQ (Equillium) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Connect Biopharma Holdings (CNTB)|Long-Term Debt to Capital Ratio Immunic Inc|Long-Term Debt to Capital ATRA (Atara Biotherapeutics)|Long-Term Debt to Equity Ratio inflarx.de IFRX|Long-Term Debt to Equity Ratio XFOR|Ratio of Long-Term Indebtedness to Capital Adicet Bio Inc. ACET|Celularity Corp - Long-Term Debt to Capital|INMB: Long-Term Debt to Capital|Long-Term Debt to Equity Barinthus Biotherapeutics|kezarlifesciences.com (KZR) - Long-Term Debt to Capital Ratio|SABS (SAB Biotherapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital Akari Therapeutics PLC|Long-Term Debt to Capital Enlivex Therapeutics (ENLV)|Long-Term Debt to Equity QTTB (q32bio.com)|GeoVax Labs, Inc. (GOVX) - Long-Term Debt to Equity|Long-Term Liabilities to Equity edesabiotech.com EDSA|Long-Term Debt to Capital iBio (IBIO)|CARM - Long-Term Debt to Capital Coefficient|XTLB: Long-Term Debt to Capital|BOLT (Bolt Biotherapeutics, Inc.) - Long-Term Debt to Capital|HCWB - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient APVO|Long-Term Debt to Equity AIM (AIM ImmunoTech)|Long-Term Debt to Equity Ratio aditxt.com (ADTX)|Long-Term Debt to Capital GRI (GRI Bio Corp)|XRTX - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Vyome Holdings Inc (HIND)|REVB - Long-Term Debt to Capital Coefficient|Indaptus Therapeutics, Inc. - Long-Term Debt to Capital|SCNI (Scinai Immunotherapeutics Ltd) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity CALI|Long-Term Debt to Equity Ratio AFMD|Long-Term Debt to Equity ALLK (Allakos Inc.)|Long-Term Debt to Equity Ratio hookipapharma.com HOOK|Long-Term Debt to Equity Ratio IGMS (IGM Biosciences)|iTeos Therapeutics Inc - Long-Term Debt to Capital|Ocean Bio (OCEA) - Long-Term Debt to Equity|TCBP - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital THRD